TAXOMET: A French Prospective Multicentric Randomized Phase II Study of Docetaxel Plus Metformin Versus Docetaxel Plus Placebo in Metastatic Castration-Resistant Prostate Cancer

CONCLUSION: MET addition failed to improve the standard DOCE regimen in mCRPC. Further research targeting tumor cell metabolism should be performed.PMID:34629300 | DOI:10.1016/j.clgc.2021.08.008

Source: Clinical Prostate Cancer - October 11, 2021 Category: Cancer & Oncology Authors: Marc Pujalte Martin Delphine Borchiellini Brice Thamphya Aline Guillot Jean-Baptiste Paoli Dominique Besson Werner Hilgers Frank Priou Claude El Kouri Benjamin Hoch Jean-Laurent Deville Renaud Schiappa Sandrine Cheli G érard Milano Jean-Fran çois Tanti Source Type: research